Qurient Co., Ltd.   Report issue

For profit Phase 2
Founded: Seongnam-si Korea, Republic of (2008)

Organization Overview

First Clinical Trial
2015
NCT02426359
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Qurient Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Hypersensitivity (Phase 2)

Neoplasm Metastasis (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 6